Marieke van Son

90 CHAPTER 5 Table 1 Continued No. patients (%) / median (range) History of ADT around primary treatment [median duration] No Yes, neo-adjuvant Yes, adjuvant 39 (78%) 4 (8%) [5.5 months] 7 (14%) [36 months] Interval between primary treatment and biochemical recurrence 101 months (25 – 228) Recurrent setting Age 71 years (59 – 83) iPSA 5 ng/ml (0.9 – 39) PSADT 17 months (3 – 73) Prostate size on MRI 33 cc (15 – 105) MRI T-stage T2a T2b T2c T3a T3b T4 19 (38%) 9 (18%) 3 (6%) 3 (6%) 14 (28%) 2 (4%) Tumor location Base Midgland Apex Combination Seminal vesicle 7 (14%) 12 (24%) 8 (16%) 10 (20%) 13 (26%) PET-CT tracer 18F-Choline 68Ga-PSMA 11 (22%) 39 (78%) Biopsy type [median no. of cores] Systematic Tumor-targeted Both 12 (24%) [8 cores] 35 (70%) [4 cores] 3 (6%) [11 cores] Gleason score* 3+3=6 3+4=7 4+3=7 Sumscore 8 Sumscore 9/10 Missing 9 (18%) 17 (34%) 11 (22%) 4 (8%) 6 (12%) 3 (6%) GTV size 3 cc (0.3 – 18.5) CTV size 8.6 cc (3.3 – 34.9) iPSA: initial prostate specific antigen level, EBRT: external beam radiation therapy, LDR-BT: low- dose-rate brachytherapy using I-125 seeds, ADT: androgen deprivation therapy, PSADT: PSA doubling time, GTV: gross tumor volume, CTV: clinical target volume.